Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1] Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility Sandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary platform for integrated development and advanced continuous manufacturing Basel, July 30, 2025 Sandoz (SIX
DZ/OTCQX
DZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE.
